GSK plc (NYSE: GSK) applies to list 250,000 shares for Share Save Plan

Rhea-AI Filing Summary

GSK plc has applied to list 250,000 new Ordinary Shares of 31¼p each on the Financial Conduct Authority’s Official List and to trade them on the London Stock Exchange. These shares are being reserved under a block listing for the GlaxoSmithKline plc Share Save Plan 2022, a plan that allows eligible employees to acquire shares in the company.

Admission of these shares is expected to become effective on 12 December 2025. Once issued, the new shares will rank equally with all existing GSK Ordinary Shares, meaning they will carry the same rights to dividends and voting as the current share capital.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of December 2025

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

Issued: 11 December 2025, London UK

Block Listing Application

Application has been made to the Financial Conduct Authority and the London Stock Exchange plc for a total of 250,000 Ordinary Shares of 31¼p each ('Shares') to be admitted to the Official List.

The Shares are being reserved under a block listing and will be issued under the GlaxoSmithKline plc Share Save Plan 2022.

When issued, the Shares will rank pari passu with the existing Ordinary Shares of 31¼p each.

Admission is expected to be effective on 12 December 2025.

V A Whyte

Company Secretary

11 December 2025

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GSK plc

(Registrant)

Date: December 11, 2025

By:/s/ VICTORIA WHYTE

--------------------------

Victoria Whyte

Authorised Signatory for and on

behalf of GSK plc

FAQ

What did GSK (GSK) announce in this Form 6-K?

GSK plc announced that it has applied for 250,000 Ordinary Shares of 31¼p each to be admitted to the Financial Conduct Authority’s Official List and to trading on the London Stock Exchange.

How many new GSK (GSK) shares are involved in this block listing?

The application covers a total of 250,000 Ordinary Shares of 31¼p each.

Under which plan will the new GSK (GSK) shares be issued?

The shares are being reserved under a block listing and will be issued under the GlaxoSmithKline plc Share Save Plan 2022.

When is admission of the new GSK (GSK) shares expected to become effective?

Admission of the 250,000 Ordinary Shares is expected to be effective on 12 December 2025.

Will the new GSK (GSK) shares have the same rights as existing shares?

Yes. When issued, the new shares will rank pari passu with the existing Ordinary Shares of 31¼p each, meaning they will have the same rights and status.

Who signed this GSK (GSK) submission and in what capacity?

The report was signed by Victoria Whyte, acting as Authorised Signatory and Company Secretary on behalf of GSK plc.